黄斑変性症(AMD)及びその他の網膜疾患治療薬の世界市場

visiongainが発行した調査報告書(VGAIN6041528)
◆英語タイトル:Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
◆商品コード:VGAIN6041528
◆発行会社(リサーチ会社):visiongain
◆発行日:2016年2月
◆ページ数:169
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥303,848見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥455,848見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥759,848見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

AMD and Other Retinal Diseases – our new study reveals trends, R&D progress, and predicted revenuesWhere is the AMD and Other Retinal Diseases market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 169 page report provides 50 tables and 42 figures. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AMD and Other Retinal Diseases market. See how to exploit the opportunities.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
• Read full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
- Philip G. Ralston, Jr., MacuCLEAR.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets:
• Wet age-related macular degeneration (wAMD)
• Dry AMD (dAMD)
• Diabetic retinopathy (DR)
• Other retinal diseases (grouped forecast).

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those eye drug revenues?
How will individual retinal medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of five prominent brands:
• Lucentis
• Eylea
• Avastin
• Visudyne
• Jetrea.

Discover how high revenues can go. See what’s happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 10 leading national markets from 2016-2026:
• United States (US)
• Japan
• Germany, France, the UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC countries).

There you will find countries with the highest revenues and potential growth. You can explore the outlook for treating ocular problems, serving doctors’ and patients’ needs. Assess the opportunity and ways to help people retain eyesight. Discover what the commercial prospects are for you and your organisation.

Leading companies and the potential for market growth
Our analyses forecasts the world market for retinal drugs will reach $17.38bn in 2020. It will achieve strong revenue expansion from 2016 to 2026. Our report reveals how high sales will go.

You can also see which companies hold the most potential. Examine eye drug developers, producers and marketers, including these firms:
• Novartis
• Roche
• Regeneron
• Bayer
• Santen
• Valeant
• Allergan

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. World AMD and Other Disease Market, 2015
2.1 What are Retinal Diseases?
2.2 Types of Retinal Diseases
2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
2.4 Nearly 200 Million People with AMD?
2.5 Over 100 Million with DR
2.6 First RVO Estimates Suggest Patient Population of 16 Million
2.7 Market to Make Rapid Pace to 2026
2.8 Eylea Became Leading drug in the Market
2.9 Regeneron the Leading Presence in the Market
2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2015
3.1 Wet AMD Still the Main Source of Revenue in the Market
3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
3.2.1 Revenue Forecasting for Wet AMD segment, 2015-2026
3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
3.3.1 Dry AMD Segment to Emerge in the Forecast Period
3.4 DR: Coming Into Clinical Focus, with DME the Main Target
3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
3.6 Projections for All Segments, 2015-2026

4. Approved Products in the AMD and Other Retinal Diseases Market, 2015-2026
4.1 Will the Current Products Dominate the Market Through 2026?
4.2 Lucentis: Second Leading Drug in the Market
4.2.1 Positive Revenue Growth Shown in Past: 2012-2015
4.2.2 Shadow of Avastin Still Hangs Over Lucentis
4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
4.2.4 Eylea: The Bigger Threat to Lucentis? (might shift in eylea section)
4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
4.2.6 Improving Cost and Compliance for Lucentis
4.2.7 Lucentis Revenue Forecast 2015-2026
4.2.8 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
4.3 Eylea: Holds the Throne?
4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
4.3.3 First Wave of Eylea’s Expansion Finally Beginning to Break?
4.3.4 Eylea into DME and Other New Indications
4.3.5 Eylea Revenue Forecast 2015-2026
4.3.6 How Far Can Eylea’s Momentum Carry It?
4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
4.4.2 Judicial Review Averted in the UK by Price Adjustment
4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
4.4.4 Roche and Novartis Challenge CATT’s Headline Conclusions
4.4.5 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
4.4.6 Avastin Revenue Forecast, 2015-2026
4.4.7 Will Anything Dislodge Avastin from its Central Position?
4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
4.5.1 Visudyne Revenue Forecast, 2015-2026
4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
4.6.1 Jetrea Revenue Forecast, 2015-2026

5. Pipeline for Wet AMD Segment, 2015-2026
5.1 The Leading Pipeline Candidates
5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
5.2.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
5.2.3 Ophthotech Partners with Novartis for Fovista
5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
5.2.5 The Move toward Combination Therapies
5.3 Other Growth Factor Targets in the Pipeline
5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
5.3.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
5.4 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
5.4.2 Binding Affinity Comparable to Eylea
5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
5.5.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
5.5.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
5.7 Other Targets Under Investigation in wAMD Drug Development
5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
5.7.7 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
5.7.8 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
5.8 Regenerative Medicine Approaches
5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

6. Pipeline for Dry AMD Segment, 2015-2026
6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
6.2 MC-1101 (MacuCLEAR): Leading the Pack?
6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
6.2.2 Novel Endpoints in Phase 3 Study
6.2.3 Can MacuCLEAR Make It?
6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
6.3.1 Data Expected in July 2016
6.3.2 Other Visual Cycle Modulators
6.4 High Hopes for Complement Inhibition in Dry AMD
6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
6.5 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
6.5.1 Iluvien (Alimera Sciences): Study terminated
6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
6.6 Neuroprotection: One of Modern Medicine’s Holy Grails
6.6.1 Tandospirone (Alcon): Not effective in GA
6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
6.7.5 First iPSC Trial in Japan in Dry AMD Patients
6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2015-2026
7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
7.2 Lucentis: The Game Changer for DR?
7.3 New Anti-VEGF Additions
7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
7.4 Steroids in Development for DR
7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
7.4.4 Cortiject (Santen): Prodrug Candidate
7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
7.5 Other Products in Development for DR
7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
7.5.3 TriLipix (Abbott): No New Development for Promising Drug
7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
7.5.5 Jetrea (ThromboGenics/Novartis): Possibilities in DME?

8. Regional Market Breakdown, 2015-2026
8.1 Which Markets Hold the Most Revenue Growth Potential?
8.2 The US: Leading Market for Retinal Diseases
8.3 Japan: Strong Market Potential
8.4 EU5: Ageing Populations to Drive Market Growth
8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Qualitative Industry and Market Analysis, 2016-2026
9.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
9.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
9.3 Opportunities: New Markets and R&D Synergies
9.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
9.5 Social: Low Diagnosis, Low Compliance
9.6 Technological: Innovation for the Eye
9.7 Economic: Off-Label Treatment and Reimbursement Issues
9.8 Political: The Demography and Diabetes Challenges

10. Research Interviews
10.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
10.1.1 Major Changes in AMD and Other Retinal Diseases Market
10.1.2 The Landscape of Emerging Markets
10.1.3 Opportunities and Plans of Marken’s Network
10.1.4 DR Market Opportunities
10.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
10.2.1 MC-1101: Progress in Clinical Trials
10.2.2 MC-1101 More Effective in Early to Mid-Range AMD
10.2.3 Partnerships and Expected Launch of MC-1101

11. Report Conclusions
11.1 The Age of Lucentis: Nearing Its Conclusion?
11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
11.3 Indications Outside Wet AMD to Gain in Importance
11.4 Dry AMD Market Has Huge Potential
11.5 Fovista Most Prominent Among the Pipeline Candidates
11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 1.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 2.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2015
Table 3.1 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2015
Table 3.2 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2014
Table 3.3 Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.4 Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
Table 3.5 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.6 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
Table 3.7 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.8 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
Table 3.9 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 3.10 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 3.11 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2015, 2020 and 2026
Table 4.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020
Table 4.4 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026
Table 4.5 Lucentis: Revenue ($bn), AGR (%), 2012-2015
Table 4.6 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
Table 4.7 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.8 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.9 Lucentis: Revenue ($bn), AGR (%), 2013-2014
Table 4.10 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.11 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.12 Avastin: Revenue ($bn), AGR (%), 2012-2014
Table 4.13 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.14 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.15 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.16 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.17 Jetrea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.18 Jetrea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 5.1 Selected R&D Pipeline for wAMD, 2015
Table 6.1 Selected R&D Pipeline for Dry AMD, 2015
Table 7.1 Selected R&D Pipeline for DR, 2015
Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.2 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.3 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.4 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.5 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.6 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.7 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.8 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.9 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.10 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 9.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2015
Table 9.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2015
Table 9.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2016-2026

List of Figures
Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2015-2026
Figure 2.2 Market Breakdown by Product Revenue ($bn), Market Share (%), 2015
Figure 2.3 Market Breakdown by Company: Market Share (%), 2015
Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 3.1 Market Breakdown by Disease Segment: Revenues ($bn), 2015
Figure 3.2 Market Breakdown by Disease Segment: Market Share (%), 2015
Figure 3.3 Wet AMD Segment Forecast: Revenue ($bn), 2015-2026
Figure 3.4 Dry AMD Segment Forecast: Revenue ($bn), 2015-2026
Figure 3.5 DR Segment Forecast: Revenue ($bn), 2015-2026
Figure 3.6 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2015-2026
Figure 3.7 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2015, 2020 and 2026
Figure 3.8 Market Breakdown by Disease Segment: Market Share (%), 2020
Figure 3.9 Market Breakdown by Disease Segment: Market Share (%), 2026
Figure 4.1 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020
Figure 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026
Figure 4.3 Market Forecast by Product: Revenue ($bn), 2015-2026
Figure 4.4 Market Breakdown by Product: Revenue ($bn), 2015, 2020 and 2026
Figure 4.5 Lucentis: Revenues Forecast ($bn), 2015-2026
Figure 4.7 Eylea Forecast: Revenue ($bn), 2015-2026
Figure 4.8 Drivers and Restraints for Eylea, 2015
Figure 4.9 Avastin Forecast: Revenue ($bn), 2015-2026
Figure 4.10 Drivers and Restraints for Avastin, 2015
Figure 4.11 Visudyne Forecast: Revenues ($bn), 2015-2026
Figure 4.12 Jetrea Forecast: Revenues ($bn), 2015-2026
Figure 8.1 Regional Breakdown: Revenue ($bn), 2015-2026
Figure 8.2 Regional Breakdown: Revenue ($bn), 2015, 2020 and 2026
Figure 8.3 Regional Market Share (%), 2015
Figure 8.4 Regional Market Share (%), 2020
Figure 8.5 Regional Market Share (%), 2026
Figure 8.6 US Market: Revenue ($bn), 2015-2026
Figure 8.7 Japan: Revenue ($bn), 2015-2026
Figure 8.8 EU5: Grouped Revenue ($bn), 2015-2026
Figure 8.9 EU5 Breakdown Forecasts: Revenue ($bn), 2015-2026
Figure 8.10 EU5 Breakdown: Market Share (%), 2015
Figure 8.11 EU5 Breakdown: Market Share (%), 2020
Figure 8.12 EU5 Breakdown: Market Share (%), 2026
Figure 8.13 BRIC Nations Forecast: Revenue ($bn), 2015-2026
Figure 8.14 BRIC Nations Forecasts: Revenue ($bn), 2015-2026
Figure 8.15 Market Share (%) within BRIC Group by Country, 2015
Figure 8.16 Market Share (%) within BRIC Group by Country, 2020
Figure 8.17 Market Share (%) within BRIC Group by Country, 2026

【レポートのキーワード】

黄斑変性症治療薬、網膜疾患治療薬、医薬品

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 黄斑変性症(AMD)及びその他の網膜疾患治療薬の世界市場(Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆